http://www.etoday.co.kr/news/section/newsview.php?idxno=1678789

Woojung Bio announced on October 25 that it is conducting epilepsy drug screening using zebrafish jointly with Bio-Pharm Solutions, a developer of medicine for rare diseases of the central nervous system (CNS). According to Woojung Bio, Prof. Kim Cheol-hee’s team of Chungnam National University and Woojung Bio cooperated in a national project last year to develop the epilepsy-inducing zebrafish model used for this screening.

IR/PR

The oral medication for infantile spasms (IS) is in phase 2 clinical trialsin Korea and the US, and the IV medication for status epilepticus (SE) is in phase 1 clinical trials in the US. The company has established new pipelines, including Alzheimer’s Disease, and is set to embark on clinical trials (phase 2)… by expanding […]

IR/PR

The oral medication for infantile spasms (IS) is in phase 2 clinical trialsin Korea and the US, and the IV medication for status epilepticus (SE) is in phase 1 clinical trials in the US. The company has established new pipelines, including Alzheimer’s Disease, and is set to embark on clinical trials (phase 2)… by expanding […]

Bio-Pharm Solutions

145, Gwanggyo-ro, Yeongtong-gu, Suwon,
Gyeonggi-do, 16229, Korea
6F, C Bldg, Advanced Institute of Convergence Technology

CONTACT

Tel: 82-31-888-9608
Fax: 82-31-888-9601

MORE

Careers: shkim@b-psol.com
Clinical Trials: hsshin@b-psol.com
Investor Inquiries: uklee@b-psol.com
BD Partnering: uklee@b-psol.com